Cargando…
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite multiple resections and adjuvant temozolomide. Treatment with topical imiquimod combined with pembrolizumab achieved remission....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559121/ https://www.ncbi.nlm.nih.gov/pubmed/34716205 http://dx.doi.org/10.1136/jitc-2020-001219 |
_version_ | 1784592694995058688 |
---|---|
author | Satish, Tejus Khan, Shaheer Levin, Matt Carvajal, Richard Yoon, Angela J |
author_facet | Satish, Tejus Khan, Shaheer Levin, Matt Carvajal, Richard Yoon, Angela J |
author_sort | Satish, Tejus |
collection | PubMed |
description | Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite multiple resections and adjuvant temozolomide. Treatment with topical imiquimod combined with pembrolizumab achieved remission. A 56-year-old woman presented with a pigmented mass on her left anterior hard palate. Biopsy revealed malignant melanoma. The patient had resection with neck dissection with 3 months of adjuvant temozolomide due to positive margins. Malignant melanoma involving the hard palate recurred 1 year later requiring additional resection. Two years later, two additional pigmented lesions were found; further resections were deferred due to expected morbidity. Following 6 weeks of topical imiquimod treatment, the lesions shrunk significantly. Adjuvant pembrolizumab was added and complete histopathologic remission was observed in 6 months. The patient remained in remission for 4 years before new melanoma in situ was diagnosed, requiring five additional months of imiquimod. As of April 2021, there is no clinical evidence of melanoma. There are limited reports of oral melanoma treated with topical imiquimod. Here, imiquimod administered in combination with pembrolizumab achieved complete pathologic response. |
format | Online Article Text |
id | pubmed-8559121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-85591212021-11-04 Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission Satish, Tejus Khan, Shaheer Levin, Matt Carvajal, Richard Yoon, Angela J J Immunother Cancer Case Report Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite multiple resections and adjuvant temozolomide. Treatment with topical imiquimod combined with pembrolizumab achieved remission. A 56-year-old woman presented with a pigmented mass on her left anterior hard palate. Biopsy revealed malignant melanoma. The patient had resection with neck dissection with 3 months of adjuvant temozolomide due to positive margins. Malignant melanoma involving the hard palate recurred 1 year later requiring additional resection. Two years later, two additional pigmented lesions were found; further resections were deferred due to expected morbidity. Following 6 weeks of topical imiquimod treatment, the lesions shrunk significantly. Adjuvant pembrolizumab was added and complete histopathologic remission was observed in 6 months. The patient remained in remission for 4 years before new melanoma in situ was diagnosed, requiring five additional months of imiquimod. As of April 2021, there is no clinical evidence of melanoma. There are limited reports of oral melanoma treated with topical imiquimod. Here, imiquimod administered in combination with pembrolizumab achieved complete pathologic response. BMJ Publishing Group 2021-10-29 /pmc/articles/PMC8559121/ /pubmed/34716205 http://dx.doi.org/10.1136/jitc-2020-001219 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Satish, Tejus Khan, Shaheer Levin, Matt Carvajal, Richard Yoon, Angela J Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title_full | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title_fullStr | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title_full_unstemmed | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title_short | Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
title_sort | treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559121/ https://www.ncbi.nlm.nih.gov/pubmed/34716205 http://dx.doi.org/10.1136/jitc-2020-001219 |
work_keys_str_mv | AT satishtejus treatmentofrecurrentmucosalmelanomaoftheoralcavitywithtopicalimiquimodandpembrolizumabachievescompletehistopathologicremission AT khanshaheer treatmentofrecurrentmucosalmelanomaoftheoralcavitywithtopicalimiquimodandpembrolizumabachievescompletehistopathologicremission AT levinmatt treatmentofrecurrentmucosalmelanomaoftheoralcavitywithtopicalimiquimodandpembrolizumabachievescompletehistopathologicremission AT carvajalrichard treatmentofrecurrentmucosalmelanomaoftheoralcavitywithtopicalimiquimodandpembrolizumabachievescompletehistopathologicremission AT yoonangelaj treatmentofrecurrentmucosalmelanomaoftheoralcavitywithtopicalimiquimodandpembrolizumabachievescompletehistopathologicremission |